https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-01 / Clin. Cancer Res. 2006 May;12(9):2817-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-01 / Clin. Cancer Res. 2006 May;12(9):2817-252006-05-01 00:00:002006-05-01 00:00:00A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-13 / Cancer Immunol. Immunother. 2006 Dec;55(12):1524-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-13 / Cancer Immunol. Immunother. 2006 Dec;55(12):1524-332006-04-13 00:00:002019-02-15 08:53:03Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-06 / Ann. Oncol. 2006 Jun;17(6):974-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-06 / Ann. Oncol. 2006 Jun;17(6):974-802006-04-06 00:00:002019-02-15 08:39:01Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-06 / Skin Pharmacol Physiol 2006;19(3):124-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-06 / Skin Pharmacol Physiol 2006;19(3):124-312006-04-06 00:00:002019-02-15 08:44:41Current state and perspectives of dendritic cell vaccination in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-03-03 / Biochem. Biophys. Res. Commun. 2006 Apr;343(1):269-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-03-03 / Biochem. Biophys. Res. Commun. 2006 Apr;343(1):269-782006-03-03 00:00:002019-02-15 08:48:22Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-872006-02-01 00:00:002019-02-15 08:48:35Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-772006-02-01 00:00:002006-02-01 00:00:00Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-18 / Immunobiology 2006;211(1-2):29-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-18 / Immunobiology 2006;211(1-2):29-362006-01-18 00:00:002019-02-15 08:44:42Immunization with antigen-pulsed dendritic cells significantly improves the immune response to weak self-antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-05 / Breast Cancer Res. 2006;8(1):101
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-05 / Breast Cancer Res. 2006;8(1):1012006-01-05 00:00:002019-02-15 08:44:41Dendritic cell defects in patients with cancer: mechanisms and significance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-82006-01-01 00:00:002019-02-15 08:44:43Genetically modified dendritic cells for therapeutic immunity
